| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
PU-02's primary target is the 5-HT3 receptor, a ligand-gated ion channel belonging to the Cys-loop family of receptors. It acts as a negative allosteric modulator, meaning it binds to a site distinct from the orthosteric (serotonin) binding site and reduces the receptor's response to serotonin. The compound is a derivative of 6-MP and shows selectivity for 5-HT3 receptors over other Cys-loop receptors. Its activity at 5-HT3A and 5-HT3AB receptors has been characterized in HEK293 cells.
|
|---|---|
| ln Vitro |
HepG2 cell viability steadily declines in response to PU02 (NMMP) (0-200 μM) (IC50=48.585 μM). PU02 (NMMP) was less hazardous to L02 cells than 6-MP after 48 hours of treatment [2]. The viability of several examined cell lines, including SMMC-7721, MDA-MB-231, RKO, and HCT-8 cells, was inhibited by PU02 (NMMP) at 6.25 or 25 μM [2]. In the G2/M phase, PU02 (NMMP) causes cell cycle arrest. HepG2 cells' expression of CDK4 and cyclin B1/D1 is time-dependently down-regulated by PU02 (NMMP), while cyclin E expression is unaffected [2]. Caspases-3 cleavage was significantly increased in PU02 (NMMP)-treated cells, suggesting increased apoptotic activity [2].
In vitro, PU-02 is a potent negative allosteric modulator of 5-HT3 receptors with IC50 values of 0.36 µM and 0.73 µM for 5-HT3A and 5-HT3AB receptors, respectively. It inhibits the proliferation of hepatocellular carcinoma (HepG2) cells associated with G2/M phase cell cycle arrest and reduced cyclin-dependent kinase (CDK) 4 and cyclin B1/D1 levels. The compound shows substantially lower activities at other Cys-loop receptors, demonstrating its selectivity. |
| ln Vivo |
In vivo, PU-02 is not used as a therapeutic agent. Its anti-proliferative effects on hepatocellular carcinoma cells have been demonstrated in vitro, but in vivo efficacy data is not provided in the search results. The compound is used as a research tool to study 5-HT3 receptor function and its role in cancer cell proliferation.
|
| Enzyme Assay |
The in vitro activity of PU-02 at 5-HT3 receptors is assessed using electrophysiological techniques or calcium imaging. Cells expressing 5-HT3 receptors (e.g., HEK293 cells transfected with 5-HT3A or 5-HT3AB subunits) are treated with various concentrations of PU-02 (typically 0.01-100 µM) for 1-5 minutes before stimulation with serotonin. The inhibition of serotonin-evoked currents or calcium influx is measured. The IC50 is determined from dose-response curves. For anti-proliferative studies, HepG2 hepatocellular carcinoma cells are treated with various concentrations of PU-02 (typically 0.1-100 µM) for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Cell cycle progression is analyzed by flow cytometry using propidium iodide staining. The expression of cyclin-dependent kinases (CDK4, cyclin B1, cyclin D1) is analyzed by Western blotting or qPCR.
|
| Cell Assay |
Apoptosis analysis [2]
Cell Types: HepG2 cells. Tested Concentrations: 6.26, 12.5, 25, 50 μM. Incubation Duration: 6, 12, 24, 36 hrs (hours). Experimental Results: Mitochondria-dependent apoptosis was induced. For cellular assays, HEK293 cells expressing 5-HT3 receptors or HepG2 hepatocellular carcinoma cells are cultured in appropriate media. Cells are treated with various concentrations of PU-02 (typically 0.01-100 µM) for defined periods. For 5-HT3 receptor studies, cells are loaded with a calcium-sensitive dye (e.g., Fluo-4) and stimulated with serotonin (typically 1-10 µM) in the presence of PU-02. The inhibition of calcium influx is measured using a fluorescence plate reader. For anti-proliferative studies, cell viability, apoptosis, and cell cycle progression are assessed using standard assays. |
| Animal Protocol |
In vivo studies with PU-02 are not detailed in the provided search results. As a research compound, it is primarily used in vitro to study 5-HT3 receptor function and cancer cell proliferation. In vivo studies would require formulation in a suitable vehicle and administration to animal models, but specific protocols are not available.
|
| ADME/Pharmacokinetics |
PU-02 has a molecular weight of 292.36 g/mol and a molecular formula of C16H12N4S. It is soluble in DMSO. The compound should be stored under appropriate conditions to maintain stability. Specific pharmacokinetic data is not available in the provided search results.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for PU-02 is not available in the provided search results. As a research compound, its safety profile has not been fully established. The compound should be handled with standard laboratory safety precautions. Its anti-proliferative effects on cancer cells suggest that it may have potential cytotoxicity to normal cells at high concentrations.
|
| References |
|
| Additional Infomation |
Structure in the first source
PU-02 is a research compound used to study 5-HT3 receptor function and its role in cancer cell proliferation. It is a potent and selective negative allosteric modulator of the 5-HT3 receptor with selectivity over other Cys-loop receptors. The compound is a derivative of 6-mercaptopurine (6-MP), an anticancer drug, and has shown anti-proliferative effects on hepatocellular carcinoma cells through G2/M phase cell cycle arrest. PU-02 is not approved for clinical use and is intended for research purposes only. It is available from chemical suppliers for research applications. |
| Molecular Formula |
C16H12N4S
|
|---|---|
| Molecular Weight |
292.36
|
| Exact Mass |
292.078
|
| CAS # |
313984-77-9
|
| PubChem CID |
720937
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.798
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
353
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C=CC=C2CSC3=NC=NC4=C3NC=N4
|
| InChi Key |
BGMSTNYJYPSLHN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12N4S/c1-2-7-13-11(4-1)5-3-6-12(13)8-21-16-14-15(18-9-17-14)19-10-20-16/h1-7,9-10H,8H2,(H,17,18,19,20)
|
| Chemical Name |
6-(naphthalen-1-ylmethylsulfanyl)-7H-purine
|
| Synonyms |
PU02; PU 02; PU-02
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~855.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (7.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4204 mL | 17.1022 mL | 34.2044 mL | |
| 5 mM | 0.6841 mL | 3.4204 mL | 6.8409 mL | |
| 10 mM | 0.3420 mL | 1.7102 mL | 3.4204 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
